Boehringer Ingelheim

This early-phase study tested a new drug (BI 836880) alone or combined with another drug (BI 754091) in 21 Japanese adults with advanced solid tumors. The main goal was to find the safest dose and check for side effects. The study is complete, and results help guide future resear…

This study tested the safety of a new medicine called BI 770371 in 28 adults with liver cirrhosis caused by MASH (a type of fatty liver disease). Participants received either the drug or a placebo as an IV infusion every 3 weeks for 12 weeks. The main goal was to see if the drug …

This study looked at the long-term safety of nintedanib in children and teens with fibrosing interstitial lung disease, a condition where lung tissue becomes scarred. Fifty-four participants took nintedanib capsules twice daily for at least 1.5 to 3 years. The goal was to see how…

This study tested a new oral drug, afatinib, against a standard chemotherapy, methotrexate, in 340 people with advanced head and neck cancer that had returned or spread and stopped responding to platinum-based treatment. The goal was to see which drug worked better at slowing can…

This study tested three different doses of an experimental oral medicine, BI 1819479, against a placebo in 322 adults aged 40 and older with idiopathic pulmonary fibrosis (IPF). The goal was to see if the drug could slow the decline in lung function, measured by breathing tests, …

This study tested a new tablet called BI 1291583 in 22 adults with cystic fibrosis and bronchiectasis (damaged airways). Participants took either the study drug or a placebo once daily for 12 weeks. The main goal was to see if the drug is safe and tolerable, and to measure its ef…

This study tested a new medicine called BI 1015550 in over 1,100 adults with idiopathic pulmonary fibrosis (IPF), a serious lung disease. Participants took either the study drug or a placebo twice daily for up to 2.5 years. The main goal was to see if the drug slowed the decline …

This study tested four different doses of an experimental drug (BI 655130) against a placebo in 152 adults with moderate to severe palmoplantar pustulosis (PPP), a skin condition causing painful pus-filled blisters on the palms and soles. The main goal was to see which dose best …

This study tested a new medicine called BI 1015550 in 1178 adults with progressive fibrosing interstitial lung diseases (PF-ILDs), a group of conditions that cause lung scarring and make breathing harder. Participants took either a low dose, a high dose, or a placebo (fake pill) …

This early-stage study tested a new drug (BI 765049) alone or with another drug (ezabenlimab) in 21 Asian adults with advanced cancers like stomach, lung, or liver cancer that had stopped responding to treatment. The goal was to find a safe dose and see if the drugs could shrink …

This study tested a new medicine called survodutide to help people with obesity lose weight. About 274 Japanese adults with a high body mass index and weight-related health problems took part. Participants received either the drug or a placebo injection once a week for 76 weeks, …

This early-stage study tested two experimental drugs, BI 765049 and ezabenlimab, in 67 adults with advanced solid tumors (like colorectal, lung, or pancreatic cancer) that hadn't responded to prior treatments. The goal was to find the highest safe dose of BI 765049 alone and comb…

This study tested a new oral drug, brigimadlin, against standard chemotherapy (doxorubicin) in 400 adults with advanced dedifferentiated liposarcoma, a rare soft-tissue cancer. Participants received either the pill every 3 weeks or chemo infusions, with the option to switch if ch…

This study tested a new medicine called Avenciguat (BI 685509) in 214 adults with scleroderma, especially those with lung fibrosis or blood vessel issues. Participants took either the medicine or a placebo three times daily for at least 11 months. The main goal was to see if the …

This study tested two experimental drugs, BI 754111 and BI 754091, that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found a safe dose; the sec…

This study tested a medicine called spesolimab in 209 adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps and tunnels. Participants received different doses of spesolimab or a placebo for about a year. The goal was to see i…

This study looked at the safety and effectiveness of taking JARDIANCE® tablets every day for a long time in 1,200 Japanese patients with chronic heart failure. Researchers tracked side effects like low blood sugar, dehydration, and kidney problems, as well as deaths and hospital …

This early-stage study tested an experimental pill, BI 3706674, in 47 adults with advanced stomach, esophageal, or gastroesophageal junction cancer that had stopped responding to other treatments. The drug works by blocking growth signals in cancer cells with a specific genetic c…

This study tested a new cancer pill called brigimadlin in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors. Participants took the pill either once every…

This study tested a new medicine called BI 655064 in 121 adults with active lupus nephritis, a kidney disease caused by lupus. The goal was to see if adding this drug to standard treatment could improve kidney function after one year. Participants received one of three doses of t…

This study tested a medicine called survodutide in 218 adults with overweight or obesity and a liver condition called NASH (fatty liver with inflammation). Participants received weekly injections of survodutide or a placebo for about a year, along with diet and exercise advice. T…

This early-phase trial tested a new drug called BI 836880 in 24 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Participants received the drug once a week through an IV. Th…

This study gave a single infusion of a medicine called spesolimab to 39 people in China with a serious skin disease called generalized pustular psoriasis (GPP) who had no other treatment options. The goal was to control the flare-up, not to cure the disease. Participants were mon…

This study tested a new medicine called survodutide (BI 456906) in 755 adults with overweight or obesity and type 2 diabetes. Participants received weekly injections of either the drug or a placebo for about 76 weeks, along with diet and exercise advice. The main goal was to see …

This study tested two or three drugs together in adults with advanced solid tumors (cancers that have spread). The main goals were to find a safe dose and see if the combination can shrink tumors. Participants took brigimadlin pills and received ezabenlimab infusions every 3 week…

This early-stage study tested a new medicine called BI 1015550 in 15 people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. The main goal was to see if the drug is safe and tolerable when taken by mouth for up to 12 weeks. Res…

This study tested a medicine called survodutide (BI 456906) in 726 adults with overweight or obesity who do not have type 2 diabetes. Participants received weekly injections of either the drug or a placebo for about 76 weeks, along with diet and exercise advice. The main goals we…

This study looked at the long-term safety and effectiveness of the drug spesolimab for adults with hidradenitis suppurativa (HS), a painful skin condition. Participants who had already completed a previous spesolimab trial received injections every two weeks for two years. The go…

This early-phase trial tested a new drug called BI 754091 in 110 adults with advanced solid tumours that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. Researchers also looked for signs that the drug might sh…

This study tested an experimental drug called BI 655130 in 22 adults with mild-to-moderate ulcerative colitis who were already taking a TNF inhibitor. The goal was to see if adding BI 655130 could help heal the lining of the colon and improve symptoms. The trial focused on safety…

This study tested an experimental pill, BI 764198, in 67 adults with focal segmental glomerulosclerosis (FSGS), a chronic kidney disease. Participants took one of three doses of the drug or a placebo daily for 12 weeks. The main goal was to see if the drug could reduce protein in…

This study tested a combination of two experimental drugs—BI 836880 (blocks blood supply to tumors) and ezabenlimab (helps the immune system attack cancer)—in adults with advanced non-small cell lung cancer and other solid tumors. The goal was to find a safe dose and see if the c…

This study tested a new cancer pill called brigimadlin (BI 907828) in 138 adults with a rare type of fat-cell cancer called dedifferentiated liposarcoma. Participants took the pill once every three weeks. Doctors monitored side effects and checked if tumors shrank. The goal was t…

This study tested a new medicine called survodutide in 307 Chinese adults with obesity or overweight who also had weight-related health problems. Participants received weekly injections of either survodutide or a placebo for about 19 months. The main goals were to see how much we…

This study tested a new immunotherapy drug, ezabenlimab (BI 754091), combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the combination could shrink or eliminate tumors. Participants received treatment as long as …

This study looked at how safe and effective the drug spesolimab is for people with a severe skin condition called generalized pustular psoriasis (GPP) who have sudden flare-ups. Researchers tracked 52 patients in Japan who were starting spesolimab for the first time, recording an…

This study tested a medicine called spesolimab in 52 adults with moderate to severe hidradenitis suppurativa, a chronic skin disease causing painful lumps and boils. Participants were randomly assigned to receive either spesolimab or a placebo (dummy treatment) as infusions and i…

This early-stage trial tested a new drug called BI 836880 in 29 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. The drug was given through an IV, and researchers monitored …

This study tested a medicine called spesolimab in 27 adults with Crohn's disease who also have fistulas near the anus. Participants received either the drug or a placebo every 4 weeks for 24 weeks. The goal was to see if the drug helps close fistulas and understand how it works. …

This study tested whether a medicine called spesolimab can prevent flare-ups of generalized pustular psoriasis (GPP), a rare and serious skin condition. It included 123 people aged 12 to 75 whose skin was clear or nearly clear at the start. Participants received either a placebo …

This study tested a medicine called iclepertin to see if it could improve memory, attention, and problem-solving in adults with schizophrenia. Over 600 participants took either iclepertin or a placebo daily for 26 weeks, while continuing their usual schizophrenia medications. Res…

This study followed 18 adults with idiopathic pulmonary fibrosis (IPF) or other progressive lung scarring who had diarrhea after starting the drug nintedanib. The goal was to see how many could control their diarrhea (fewer than 3 loose stools per day) after 12 weeks while stayin…

This study tested an experimental drug called BI 655130 in 59 adults with palmoplantar pustulosis (PPP), a skin condition causing painful pustules on the palms and soles. The goal was to see if the drug safely reduces the severity of pustules and redness compared to a placebo. Pa…

This study tested a single dose of a drug called spesolimab in 53 people with a rare and severe type of psoriasis that causes painful pus-filled blisters all over the body. The goal was to see if it could quickly clear these blisters within one week compared to a placebo. The dru…

This study tested an experimental medicine called BI 1569912 in 243 adults aged 18–65 with major depressive disorder that didn't improve with prior treatments. Participants took either a placebo or one of three doses of the medicine daily for 6 weeks, while continuing their usual…

This study tested a daily tablet called iclepertin to see if it could improve memory, attention, and problem-solving in adults with schizophrenia. Over 600 participants took either iclepertin or a placebo for 26 weeks while continuing their usual schizophrenia medication. Researc…

This study checked whether the experimental drug survodutide (BI 456906) causes any heart rhythm changes in 110 adults with overweight or obesity. Participants received weekly injections of survodutide or a placebo for about 30 weeks, along with a single dose of moxifloxacin (a d…

This study tested a new medicine called iclepertin in 620 adults with schizophrenia to see if it could improve memory and thinking. Participants took either iclepertin or a placebo daily for 26 weeks, while continuing their usual schizophrenia medication. Researchers measured cha…

This study looked at whether atomoxetine, a medication for ADHD, can reduce impulsive behavior in adults aged 18 to 45 with moderate ADHD. 63 participants were randomly assigned to receive either atomoxetine or a placebo. Researchers measured impulsivity using two standard questi…

This early-stage study tested a new medicine called BI 3006337 in 64 adults who are overweight or have obesity and also have fatty liver disease. The main goal was to see if different doses of the weekly injection are safe and tolerable. Participants received either the drug or a…

This study tested an experimental drug called BI 655130 in 51 adults with moderate to severe atopic dermatitis (eczema). Participants received either the drug or a placebo through an IV, and researchers measured changes in skin redness, thickness, and itching over 16 weeks. The g…

This early-stage study tested a single dose of BI 1015550 in 24 healthy Chinese adults to see how the drug is processed by the body and whether it is safe. Participants were closely monitored for side effects and drug levels in their blood. The study is complete and provides basi…

This study looked at how a new drug called BI 1810631 is absorbed, broken down, and removed from the body in 15 healthy men. Part A measured how much of the drug was recovered in urine and stool. Part B compared how well the tablet form works versus a tiny IV dose. The goal was t…

This study looked at how taking multiple doses of zongertinib changes the way the body processes three other drugs (midazolam, omeprazole, and repaglinide) in 16 healthy men. Participants received the drugs alone and then again after taking zongertinib for several days. The goal …

This study looked at how a new drug called BI 764198 changes the amount of metformin in the blood. Fourteen healthy adults took metformin with and without BI 764198 to see if the combination affects drug levels. The goal was to gather safety and interaction data, not to treat any…

This study looked at how a new drug called BI 425809 changes the way the body processes another drug, midazolam. It involved 15 healthy men who took both drugs. The goal was to see if BI 425809 affects a key liver enzyme, which could change how other drugs work. This helps doctor…

This study looked at how taking multiple doses of an experimental drug (BI 1569912) changes the way the body processes three common medicines (repaglinide, midazolam, and bupropion). Eighteen healthy adults took the drugs alone and together, and researchers measured drug levels i…

This study checked whether two different pill versions of the drug nerandomilast are processed the same way in the body. 64 healthy adults each took a single dose of both versions at different times. The goal was to see if the new version works like the one used in later-stage st…

This study looked at how the antibiotic rifampicin changes the way the body processes an experimental drug called BI 425809, which is being developed for Alzheimer's disease. Sixteen healthy men took a single dose of BI 425809 alone and then again after several days of rifampicin…

This early-stage trial tested the safety and tolerability of a new drug called BI 1015550 in 42 healthy men. Participants received either a single dose or multiple doses of the drug. The study focused on side effects and how the drug moves through the body, not on treating any di…

This study looked at how a new drug called BI 1291583 moves through and leaves the body. Eight healthy men took a single dose with a radioactive tag so scientists could track it in urine and stool. The goal was to understand how the drug is broken down and eliminated, not to trea…

This study looked at how a drug called BI 655130 enters the body when injected in different places (belly vs. thigh) and in different doses. It involved 48 healthy adults aged 18 to 50. The goal was to understand the drug's behavior, not to treat any disease.

This early-stage study tested a single dose of an experimental drug called BI 425809 in 83 healthy men. The main goal was to check for side effects and see how the drug moves through the body. Researchers also compared a liquid form to a tablet and looked at whether food changes …

This early-stage study tested the safety and tolerability of a new drug called BI 1569912 in 56 healthy Japanese men. Participants received either a single dose or multiple doses of the drug or a placebo. The main goal was to check for side effects and measure how the drug behave…

This study looked at how taking bosentan (a drug that can speed up liver processing) changes the levels of nerandomilast in the blood. Sixteen healthy men took nerandomilast alone and then again after several days of bosentan. The goal was purely to gather safety and dosing infor…

This study looked at how the drug BI 1015550 moves through and leaves the body of healthy men. Six participants took a single dose, and researchers measured the drug and its breakdown products in blood, urine, and stool. The goal was to understand how the body handles the drug, n…

This early-stage trial studied the safety and how the body handles multiple doses of an experimental drug called BI 3810477. It involved 47 healthy adults aged 18 to 60. The goal was to check for side effects and measure drug levels in the blood, not to treat any disease.

This study looked at how a new drug called BI 1015550 moves through the bodies of 12 healthy Japanese men. The goal was to measure drug levels in the blood after taking different single doses. This information helps doctors understand the right dose for future studies.

This early-stage study in 6 healthy men measured how much of the experimental drug BI 425809 enters the bloodstream after swallowing a pill. Participants received a pill plus a tiny radioactive tracer dose into a vein. The goal was to understand the drug's absorption, not to trea…

This study looked at how taking the drug zongertinib with or without food changes the amount that gets into the blood. Sixteen healthy men each took one dose of the drug in two different conditions: after a high-fat meal and on an empty stomach. The results will help doctors deci…

This study looked at how taking multiple doses of carbamazepine (a common seizure medicine) changes the way the body processes a single dose of an experimental drug called zongertinib. Sixteen healthy men participated. The goal was to understand if carbamazepine affects zongertin…

This study looked at how a new weight-loss drug called BI 456906 affects the way the body processes three common drugs: bupropion, caffeine, and midazolam. Thirty-four healthy adults with overweight or obesity took these drugs alone and then again while receiving weekly injection…

This study looked at whether zongertinib tablets made by two different manufacturers are absorbed the same way in the body. It involved 56 healthy adults who took a single dose of each version at different times. The goal was to check bioequivalence, not to treat any disease. No …

This study looked at the safety of the drug Ofev in 425 Japanese patients with a type of progressive lung scarring called PF-ILD. The main goal was to track any side effects, especially liver problems, in everyday medical practice. The study did not test if the drug works, but ra…

This study looked at how healthy men absorb, break down, and eliminate a drug called BI 425809. Six men took a single dose, and researchers measured the drug and its byproducts in urine and stool. The goal was to understand the drug's journey through the body, not to treat any di…

This study looked at how a new drug called BI 3000202 affects the way the body handles two other medicines: rosuvastatin (used for cholesterol) and digoxin (used for heart conditions). Fourteen healthy adults took part. The goal was to measure drug levels in the blood, not to tre…

This study looked at how the drug BI 1015550 is processed in people with mild or moderate liver problems compared to those with healthy livers. Twenty-eight adults took a single dose of the drug, and researchers measured its levels in the blood over time. The goal was to understa…

This study looked at how a new cancer drug (BI 907828) interacts with two common medicines: rifampicin (an antibiotic) and itraconazole (an antifungal). 33 adults with advanced solid tumors took BI 907828 alone and then with each other drug. Researchers measured drug levels in th…

This study tested how well the body absorbs a new drug, BI 1015550, when given in different pill forms and with or without food. Twenty-four healthy adults took single doses of the drug in three different ways to compare absorption. The goal was to find the best pill form and und…

This study looked at how taking multiple doses of an experimental drug (BI 1015550) changes the way the body breaks down a common sedative (midazolam). Fifteen healthy men aged 18 to 55 took part. The goal was to see if BI 1015550 speeds up or slows down the metabolism of midazol…

This early-stage study looked at how a new drug called BI 425809 changes the way the body processes four common medicines (midazolam, warfarin, omeprazole, and digoxin). Thirteen healthy men took the drugs in a controlled setting, and researchers measured their blood levels over …

This study looked at how taking the experimental drug BI 1015550 with or without food changes the amount of drug in the blood. 18 healthy adults took a single dose under both conditions. The results help researchers understand the best way to take the drug in future studies.

This study looked at whether taking itraconazole changes how much of another drug, BI 764198, stays in the blood. Fourteen healthy men took both medicines at different times, and researchers measured drug levels. The goal was to understand how these drugs interact, which helps do…

This study involved over 1,300 adults with rheumatoid arthritis who had at least two risk factors for interstitial lung disease (ILD), such as being male, a smoker, or older at diagnosis. Researchers used CT scans to check for ILD and created a prediction model to help doctors de…

This study looked at how the antifungal drug fluconazole changes the way the body processes an experimental drug called BI 425809. Fifteen healthy men took BI 425809 alone and then again while also taking fluconazole. The goal was to measure drug levels in the blood, not to treat…

This study looked at how a new drug, BI 1569912, moves through and leaves the body. Eight healthy men took a single oral dose with a radioactive tracer, plus a tiny intravenous dose with a different tracer. The goal was to measure how much drug is absorbed, how it's broken down, …

This study looked at how a new drug, zongertinib, changes the way other medicines are processed in the body. Thirty-two healthy men took zongertinib along with common drugs like blood thinners, cholesterol medicine, diabetes medicine, and a water pill. Researchers measured drug l…

This study checked whether a single dose of the experimental drug BI 1015550 affects the heart's electrical activity in 46 healthy adults aged 18 to 50. Participants received low and high doses of the drug, a placebo, and an active control (moxifloxacin) to compare effects. The m…

This study looked at how the antibiotic erythromycin changes the way a new drug, BI 1291583, stays in the body. Twenty healthy adults took both drugs to measure drug levels. The goal was to gather information, not to treat any disease.

This early-stage study tested an experimental drug called BI 655130 in 36 healthy adults. The main goal was to see how well the drug is absorbed when given as a shot under the skin compared to through an IV. Researchers also checked safety and how the drug behaves in the body. No…

This study looked at whether taking the drug BI 425809 with food changes how much of it gets into the blood. Sixteen healthy adults took the drug once with a meal and once on an empty stomach. The results will help doctors know if the drug should be taken with or without food.

This study looked at two different versions of the drug nerandomilast and how food affects the new version. Fifteen healthy adults took single doses in a random order. The goal was to see how the drug is absorbed and processed by the body.

This study tested how the antifungal drug itraconazole changes the way a new drug, BI 706321, is processed in the body. Fourteen healthy men took a single dose of BI 706321 alone and later with itraconazole. The goal was to measure drug levels in the blood to understand the inter…

This study looked at how two different pill versions of a new drug, BI 1810631, are absorbed in the body. It involved 13 healthy men who took single doses of each version, and also tested how food and a common stomach acid medicine (rabeprazole) affected absorption. The goal was …

This early-stage study tested a new drug called BI 3006337 in 36 healthy Japanese men to see if it is safe and how the body handles it. Participants received either a single shot or multiple shots over 6 weeks. The goal was to gather safety and drug-level data, not to treat any d…

This study in 8 healthy men aims to understand how the drug BI 1584862 is absorbed, broken down, and eliminated from the body. Participants take a single oral dose with a radioactive label and a tiny intravenous dose with a stable label. Researchers measure the drug and its bypro…

This study looked at how the experimental drug BI 3000202 is absorbed, broken down, and removed from the body in 12 healthy adults. In one part, participants took the drug as a liquid to measure how much leaves in urine and stool. In another part, they took a tablet and a tiny in…

This study looked at how taking multiple doses of a new drug (BI 1015550) changes the way the body processes two other drugs (nintedanib and pirfenidone). Fourteen healthy men took part. The goal was to see if BI 1015550 speeds up or slows down the breakdown of these drugs, which…

This early-stage study tested a new drug called BI 1015550 in 16 healthy Japanese men to see if it is safe and how the body handles it. Participants received a single rising dose of the drug or a placebo. The goal was to check for side effects and measure drug levels in the blood…

This study looked at how taking carbamazepine (a seizure medicine) changes the way the body processes nerandomilast, an experimental drug. Sixteen healthy men took both drugs, and researchers measured drug levels in their blood. The goal was to gather safety and interaction data,…

This study looked at how different levels of kidney function affect the way the experimental brain drug iclepertin is processed in the body. 36 adults with normal or impaired kidneys took a single dose of iclepertin. Researchers measured drug levels in the blood to see if kidney …

This study looked at how the body handles four common medicines (rosuvastatin, digoxin, metformin, and furosemide) in healthy adults and in people with liver cirrhosis. Researchers measured drug levels in the blood to see if liver disease changes how these drugs are processed. Th…

This study looked at how much of the experimental drug BI 1015550 gets into the bloodstream when taken as a pill compared to when given directly into a vein. Eight healthy men took part. The results help researchers understand the drug's behavior in the body, which is important f…

This study tested whether two different versions of the drug nerandomilast are absorbed the same way in the body. It involved 64 healthy adults who took a single dose of each version on separate days. The goal was to confirm the new version works like the one used in later-stage …

This early study tested a new drug called BI 655130 in 8 adults with moderate to severe ulcerative colitis. The main goal was to see how the drug affects genes in the gut lining, not to prove it works as a treatment. Researchers also checked safety and inflammation markers. Becau…

This early-stage study tested a new drug called BI 425809 in 25 healthy men to see how much of it reaches the brain. Researchers measured drug levels in blood and spinal fluid after different doses. The goal was to understand the drug's safety and how it behaves in the body, not …

This completed study looked at over 10,000 people in France who were prescribed antifibrotic drugs for idiopathic pulmonary fibrosis (a serious lung disease). The goal was to see how many patients continued their treatment for up to 30 months and what factors might cause them to …

This study looked at how the body absorbs empagliflozin, a diabetes medication, when taken as a whole tablet or dissolved in water and mixed with food. Fourteen healthy adults participated in this crossover trial. The goal was to see if taking the pill dissolved in water changes …

This study looked at how the antifungal itraconazole changes the amount of an experimental drug (BI 1815368) in the blood of 14 healthy men. Participants took the experimental drug alone and later with itraconazole to compare drug levels. The goal was to understand if dose adjust…

This study looked at how taking bosentan (a drug that affects liver enzymes) changes the amount of another drug, BI 425809, in the blood. Fourteen healthy men took BI 425809 alone and then again with bosentan. The goal was to see if bosentan reduces the levels of BI 425809, which…

This study looked at how the body absorbs two different combinations of the drugs vicadrostat and empagliflozin. It also checked whether food changes drug levels. Thirty-two healthy adults took a single dose of each combination. The goal was to gather information, not to treat an…

This study looked at how different levels of kidney function affect the amount of a new medicine (BI 456906) in the blood. The medicine is being developed for obesity and liver problems. 42 adults with or without kidney problems received a single injection. Researchers compared b…

This study followed 158 adults with a progressive form of lung scarring (not IPF) who were starting the medication nintedanib. Researchers wanted to see if changes in lung function over 52 weeks were linked to changes in cough and shortness of breath, as reported on a special que…

This study looked at how taking the antifungal drug itraconazole changes the amount of the experimental drug BI 1015550 in the blood. Sixteen healthy men received a single dose of BI 1015550 alone and again while taking itraconazole. The goal was to see if the combination alters …

This early-stage study tested a new drug called BI 425809 in 49 healthy Japanese and Chinese men. The main goal was to check safety and how the drug moves through the body after a single dose. No treatment for any disease was given; this was purely a safety and drug-level study.

This study tested two new versions of a tablet (BI 425809) against an older version to see how well the body absorbs each one. It involved 18 healthy adults aged 18 to 55. The goal was simply to compare the formulations, not to treat any disease.

This study looked at how taking multiple doses of itraconazole (an antifungal) changes the way the body processes a single dose of the experimental cancer drug zongertinib. Sixteen healthy men participated to measure drug levels in the blood. The results will help doctors underst…

This study looked at how taking multiple doses of itraconazole, a strong CYP3A4 inhibitor, changes the way the body processes a single dose of BI 3031185. Fourteen healthy male volunteers participated. The goal was to measure drug levels in the blood to understand the interaction…

This study looked at whether taking multiple doses of the drug Iclepertin affects how the body processes a common birth control pill (Microgynon) in healthy women aged 18-35. Nineteen participants took the birth control pill with and without Iclepertin, and researchers measured d…

This study looked at how the experimental brain medicine iclepertin is processed in people with and without liver problems. About 29 adults took a single dose of the drug, and researchers measured its levels in the blood. The goal was to see if liver impairment changes how the bo…

This early-stage study tested the safety and how the body handles a new drug called BI 425809 in 96 healthy young and elderly volunteers. Participants took the drug as tablets once daily for 12 days, and researchers also compared taking it in the morning versus evening. The goal …